Loading
NASDAQHealthcareBiotechnology
Latest quote
$25.27
−$0.64 · -2.47%
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Latest quote
$25.27
−$0.64 · -2.47%
After-hours
$25.27
$0.00 · 0.00%
Oct 9, 4:10 PM ET
Regular session · ET · Market data may be delayed.
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Day range
Current $25.27
52-week range
Current $25.27
Regular session · ET · Market data may be delayed.
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Day range
Current $25.27
52-week range
Current $25.27
| Metric (USD) | FY2025 |
|---|---|
| Revenue | 74.21M USD |
| Cost of goods sold | 32.51M USD |
| Gross profit | 41.71M USD |
| Research and development | 37.47M USD |
| Selling, general, and administrative | 35.57M USD |
| Operating expenses | 73.04M USD |
| Interest income | 2.16M USD |
| Interest expense | 401K USD |
| Depreciation and amortization | 3.86M USD |
| Operating income | −31.33M USD |
| Net income | −29.82M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$33.50
32.57% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
